- Cidara Therapeutics Inc (NASDAQ:CDTX) announced efficacy and safety data from a planned interim analysis of the ongoing Phase 2a trial evaluating the pre-exposure prophylactic activity of CD388 against the H3N2 influenza A virus strain.
- As evidenced by animal efficacy studies, CD388 has the potential to be a long-acting antiviral drug designed to deliver universal prevention of seasonal and pandemic influenza A and B strains.
- A single dose of CD388 decreased influenza viral replication in the upper respiratory tract and lowered influenza incidence rate in a human challenge model compared to a placebo.
- The study is being conducted under an exclusive worldwide license and collaboration agreement with Janssen Pharmaceuticals Inc, a unit of Johnson & Johnson (NYSE:JNJ), to develop and commercialize Cidara’s Cloudbreak drug-Fc conjugates (DFCs) for the prevention of seasonal and pandemic influenza.
- The interim analysis is based on 56 subjects, with 28 receiving a single dose of CD388 (150 mg) and 28 receiving a placebo.
- Treatment with CD388 was generally well-tolerated, with no treatment-emergent adverse events leading to study discontinuation or serious adverse events reported in the interim analysis.
- Price Action: CDTX shares are up 12.50% at $1.70 on the last check Wednesday.
Sanofi Posts Upbeat Q1 Earnings, Sales Buoyed By Blockbuster Dupixent Sales
French drugmaker Sanofi SA (NASDAQ: SNY) reported an 8.7% Y/Y (+9.3% on constant currency) rise in
